The Effectiveness of a Novel Software Program to Help in ROTEM Interpretation
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Natalie Silverton, MD
- Phone Number: 8015816393
- Email: natalie.silverton@hsc.utah.edu
Study Contact Backup
- Name: Jacob Steenblik
- Phone Number: 8015811216
- Email: jacob.steenblik@hsc.utah.edu
Study Locations
-
-
Utah
-
Salt Lake City, Utah, United States, 84132
- University of Utah
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Current residents and attending physicians in the University of Utah Department of Anesthesiology who have a range of experience and exposure to thromboelastography
Exclusion Criteria:
- Refusal to consent or no longer an active member of the University of Utah Department of Anesthesiology
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Software Tutorial
Participants will be asked to interpret a series of ROTEM studies before and after a tutorial on a novel ROTEM interpretation software.
|
Clinicians will be asked to interpret ROTEM studies before and after exposure to a novel ROTEM interpretation software.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Overall Proportion of Correct Clinician Responses Pre- and Post-application
Time Frame: At pre-application (baseline) and post-application (up to 15 minutes)
|
Proportion of correct of clinician responses compared to a reference standard.
|
At pre-application (baseline) and post-application (up to 15 minutes)
|
|
Overall Proportion of True Negative Clinician Responses Pre- and Post-application
Time Frame: At pre-application (baseline) and post-application (up to 15 minutes)
|
Proportion of correct of clinician responses compared to a reference standard.
|
At pre-application (baseline) and post-application (up to 15 minutes)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Proportion of Correct Clinician Responses by Question Type Pre and Post Application
Time Frame: At pre-application (baseline) and post-application (up to 15 minutes)
|
Proportion of correct responses with 95% confidence intervals for cryoprecipitate, fresh frozen plasma, multiple-product scenarios, normal patterns, and platelets, shown separately for pre- and post-application
|
At pre-application (baseline) and post-application (up to 15 minutes)
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 00159279
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.